Cited by 908Liver Disease and TransplantationSepsis Diagnosis and TreatmentGut microbiota and health

Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

Open access
Jalan, Rajiv, Fernandez, Javier, Wiest, Reiner, Schnabl, Bernd, Moreau, Richard, Angeli, Paolo, Stadlbauer, Vanessa, Gustot, Thierry +16 more·2014·Journal of Hepatology

Abstract

Bacterial infections are very common and represent one of the most important reasons of progression of liver failure, development of liver-related complications, and mortality in patients with cirrhosis. In fact, bacterial infections may be a triggering factor for the occurrence of gastrointestinal bleeding, hypervolemic hyponatremia, hepatic encephalopathy, kidney failure, and development of acute-on-chronic liver failure. Moreover, infections are a very common cause of repeated hospitalizations, impaired health-related quality of life, and increased healthcare costs in cirrhosis. Bacterial infections develop as a consequence of immune dysfunction that occurs progressively during the course of cirrhosis. In a significant proportion of patients, infections are caused by gram-negative bacteria from intestinal origin, yet gram-positive bacteria are a frequent cause of infection, particularly in hospitalized patients. In recent years, infections caused by multidrug-resistant bacteria are becoming an important clinical problem in many countries. The reduction of the negative clinical impact of infections in patients with cirrhosis may be achieved by a combination of prophylactic measures, such as administration of antibiotics, to reduce the occurrence of infections in high-risk groups together with early identification and management of infection once it has developed. Investigation on the mechanisms of altered gut microflora, translocation of bacteria, and immune dysfunction may help develop more effective and safe methods of prevention compared to those that are currently available. Moreover, research on biomarkers of early infection may be useful in early diagnosis and treatment of infections. The current manuscript reports an in-depth review and a position statement on bacterial infections in cirrhosis.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2014.01.024

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Norfloxacin is one of the drugs of choice for primary or secondary prophylaxis of spontaneous bacterial peritonitis and infections in high-risk cirrhosis patients.

    “Norfloxacin, a poorly absorbed quinolone, is currently one of the drugs of choice for the primary or secondary prophylaxis of spontaneous bacterial peritonitis and infections in high-risk patients with cirrhosis 108.”

Cites

Flagged first, then by citations

1 of the 165 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., Albillos, A., Lammert, F., Wilmer, A., Mookerjee, R., Vila, J., Garcia-Martinez, R., Wendon, J., Such, J., Cordoba, J., Sanyal, A., Garcia-Tsao, G., Arroyo, V., Burroughs, A., & Ginès, P.
Affiliations
  • The Royal Free Hospital (GB)
  • University Hospital of Bern (CH)
  • University of California San Diego (US)
  • Inserm (FR)
  • University of Padua (IT)
  • Medical University of Graz (AT)
  • Université Libre de Bruxelles (BE)
  • University of Bologna (IT)
  • Universitätsklinikum des Saarlandes (DE)
  • Universitair Ziekenhuis Leuven (BE)
  • King's College London (GB)
  • Instituto de Salud Carlos III (ES)
  • Virginia Commonwealth University (US)
Corresponding author
Ginès, Pere
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2014-06
Volume
60
Issue
6
Pages
1310-1324
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2136919496
Cited by
906
References
165
Citations by year
2026: 35 · 2025: 52 · 2024: 63 · 2023: 56 · 2022: 88 · 2021: 105 · 2020: 83 · 2019: 79 · 2018: 102 · 2017: 84 · 2016: 72 · 2015: 65 · 2014: 22
FWCI
45.19
Type
journal article
Language
en
Open access
Locations
  • Journal of Hepatology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • BORIS (University Library Bern) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
  • Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
  • Padua Research Archive (University of Padova) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
Funders
Fondo de Investigación Sanitaria (FIS PI08/0126, FIS PI12/00330)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
bacterial infection, liver cirrhosis, immune dysfunction, Gram-negative bacteria, Gram-positive bacteria, multidrug-resistant bacteria, infection control, antibiotic prophylaxis, gut microbiota, bacterial translocation, acute-on-chronic liver failure, infection biomarkers, early infection detection, hospitalization
MeSH terms
Anti-Bacterial Agents, Bacterial Infections, Gastroenterology, Humans, Liver Cirrhosis, Practice Guidelines as Topic, Drug Resistance, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review